| Prev Close | 0.43 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.29 / 1.32 |
| Avg Volume | 1.06M |
| Exchange | NASDAQ |
| Shares Outstanding | 242.38M |
| Market Cap | 104.22M |
| EPS | -0.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Peregrine Pharmaceuticals Provides Update On Oral Presentation Of Top-Line Data From Phase III SUNRISE Trial Of Bavituximab At European Society For Medical Oncology (ESMO) 2016 Congress
Ongoing Biomarker Analysis Has Identified a Biomarker that is Associated with a Statistically Significant Improvement in Overall Survival for Patients Receiving the Bavituximab Combination
National Comprehensive Cancer Network (NCCN) Awards Three Grants For Combination Studies Of Peregrine Pharmaceuticals' Bavituximab In Multiple Cancers
Peregrine's Novel PS-Targeting Immuno-Oncology (I-O) Agent to be Combined with Immunotherapy and Traditional Cancer Treatments in Studies Focused on Glioblastoma, Head and Neck Cancer and Hepatocellular Carcinoma
Avid Bioservices To Participate In Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit
Company Selected for Presentation and Panel Participation; Will Showcase Industry-Leading Contract Manufacturing Capabilities Spanning Early Stage Development to Commercialization
Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark
In trading on Thursday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 15% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $17.22 on the day. As of last close, PPHMP was trading at a 29.60% discount to its liquidation preference amount.
Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark
In trading on Wednesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 15% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $17.15 on the day. As of last close, PPHMP was trading at a 29.00% discount to its liquidation preference amount.
Peregrine Pharmaceuticals Announces Formal Commissioning Of New, State-of-the-Art Commercial Manufacturing Facility
-- Facility Being Operated by Avid Bioservices Subsidiary With Capacity to Potentially Generate Additional $40 Million in Annual Revenue --
Peregrine Pharmaceuticals Provides Update On Phase III SUNRISE Trial Of Bavituximab
Conference Call With Management Scheduled for 4:30 p.m. Eastern Time
First Week of October 21st Options Trading For Peregrine Pharmaceuticals (PPHM)
Investors in Peregrine Pharmaceuticals Inc. saw new options begin trading this week, for the October 21st expiration.
Peregrine Pharmaceuticals And National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration To Evaluate Novel Cancer Treatment Combinations With Bavituximab
NCCN Alliance Includes 26 Leading Cancer Centers and World-Class Thought Leaders on Innovative Cancer Combination Therapies
Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 12% Yield Mark
In trading on Tuesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 12% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $21.59 on the day. As of last close, PPHMP was trading at a 12.40% discount to its liquidation preference amount.
